516 patents
Page 2 of 26
Utility
Topical Treatment of Vitiligo by a Jak Inhibitor
9 Nov 23
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen BUTLER, Jim LEE, Kang SUN, Fiona KUO, Michael HOWELL
Filed: 8 Dec 22
Utility
Imidazopyrimidines and Triazolopyrimidines As A2A / A2B Inhibitors
9 Nov 23
Xiaozhao Wang, Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
Filed: 13 Apr 23
Utility
ALK2 Inhibitors for the Treatment of Anemia
26 Oct 23
Provided herein are methods of treating anemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an ALK2 inhibitor.
Francis Séguy, Ekaterine Asatiani, Yaoyu Chen
Filed: 28 Jun 23
Utility
Bicyclic Heterocycles As FGFR Inhibitors
26 Oct 23
Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
Filed: 26 Jan 23
Utility
Pyrazolopyridine compounds and uses thereof
24 Oct 23
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Wenqing Yao
Filed: 7 Jan 21
Utility
Solid forms of an HPK1 inhibitor
17 Oct 23
The present invention relates to salt forms of the hematopoietic progenitor kinase 1 (HPK1) inhibitors N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide and N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide, including methods of preparation thereof, where the compounds are useful in the treatment of HPK1 mediated diseases such as cancer.
Zhongjiang Jia, William Frietze
Filed: 25 Jun 21
Utility
Heterocyclic compounds as immunomodulators
17 Oct 23
Liangxing Wu, Jingwei Li, Wenqing Yao
Filed: 15 Feb 22
Utility
Process of preparing a PD-1/PD-L1 inhibitor
10 Oct 23
The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
Filed: 5 Nov 21
Utility
Tricyclic urea compounds as JAK2 V617F inhibitors
10 Oct 23
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
Filed: 1 Jul 21
Utility
Heterocyclic compounds as PI3K-γ inhibitors
3 Oct 23
Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
Filed: 24 Jun 21
Utility
Bicyclic dione compounds as inhibitors of KRAS
26 Sep 23
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds.
Taisheng Huang, Xiaozhao Wang, Wenqing Yao
Filed: 1 Oct 21
Utility
Tricyclic pyridone compounds as JAK2 V617F inhibitors
26 Sep 23
The present application provides tricyclic pyridone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Kai Liu, Onur Atasoylu, Yu Bai, Andrew W. Buesking, Leah C. Konkol, Cheng-Tsung Lai, Song Mei, Jun Pan, Liangxing Wu, Wenqing Yao
Filed: 1 Jul 21
Utility
Topical Treatment of Vitiligo by a Jak Inhibitor
21 Sep 23
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof based on results from long term clinical studies.
Kathleen BUTLER, Jim Lee, Kang SUN, Fiona KUO, Michael HOWELL
Filed: 28 Feb 23
Utility
Ruxolitinib Formulation for Reduction of Itch In Atopic Dermatitis
21 Sep 23
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, Jim Lee
Filed: 28 Oct 22
Utility
Tricyclic Urea Compounds As JAK2 V617F Inhibitors
21 Sep 23
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Cooper Taylor, Yanran Ai, Chunhong He, Ke Zhang, Zhitong Zheng, Eddy W. Yue
Filed: 16 Mar 23
Utility
Crystalline form of a PD-1/PD-L1 inhibitor
19 Sep 23
The present invention relates to crystalline forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, and related synthetic intermediates, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
Zhongjiang Jia, Shili Chen, Mei Li, Pingli Liu, Yongchun Pan, Yongzhong Wu, Jiacheng Zhou
Filed: 5 Nov 21
Utility
Salts of a PD-1/PD-L1 inhibitor
12 Sep 23
The present invention relates to salt forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
Zhongjiang Jia, Pingli Liu, David J. Meloni, Yongchun Pan, Yongzhong Wu, Jiacheng Zhou, Qun Li
Filed: 7 Aug 20
Utility
Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
12 Sep 23
The present application provides pyrrolotriazine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Zhiyong Yu, Liangxing Wu, Wenqing Yao
Filed: 17 Jun 21
Utility
Topical Formulation for a Jak Inhibitor
7 Sep 23
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 28 Dec 22
Utility
Solid Forms, Salts, and Processes of Preparation of a CDK2 Inhibitor
7 Sep 23
Joseph A. Sclafani, Daniel Carper, Zhongjiang Jia, Eric Shi, Aibin Zhang, Huaping Zhang, Wenxing Guo
Filed: 7 Mar 23